Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Bring the benefits of science to mankind
- There is a large vaccine ecosystem
- The role of manufacturing
- Brief outline of how to make a vaccine
- What are vaccine antigens made of?
- How much vaccine do we need to make? (1)
- How much vaccine do we need to make? (2)
- How do we make biological molecules?
- Scale-up in discovery research
- Transfer from research to manufacturing
- Technology Transfer - Knowledge Transfer
- Process development & scale-up
- Regulatory problem of scaling-up
- How to scale up (1)
- How to scale up (2)
Topics Covered
- The vaccine ecosystem
- How to make a vaccine (brief outline)
- Vaccine antigens
- Assessing vaccine quantities
- Technology & knowledge transfer
- Process development and scaling-up
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gerson, D. (2023, June 12). Vaccine manufacturing 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 24, 2024, from https://doi.org/10.69645/ZGVQ8638.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Don Gerson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Vaccine manufacturing 1
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, today I'm going to talk
about vaccine manufacturing.
My name is Donald Gerson
and I have a long history
in vaccine manufacturing.
I received a PhD in biophysics from
McGill University a long time ago.
I've spent approximately the
last 30 years making most
of the commercial vaccines
that are available today
and was involved in
making the very first
of all three major
conjugate vaccines that
are currently available worldwide.
So today we're going to talk
about how you make vaccines,
and why to make vaccines,
and what's involved.
I'm going to focus on
the kinds of things
that you can't so
easily read in a book.
So some of the, I hope,
wisdom behind this,
rather than just some
technical details
that you could read elsewhere.
0:51
So first of all, there are an
awful lot of benefits to vaccines,
but they came initially
as scientific discovery.
So in order to benefit humanity
from a scientific discovery,
you have to convert that
discovery into widely
used products or services.
And that's just as
true for vaccines as it
is for cellular phones, or
any other electronic device,
or information technology process.
There's a huge effort required
to go from the initial scientific
discovery to something
that's useful and makes
a difference to people's lives.
Now, in the particular
issue of making vaccines,
there are only several hundred
serious pathogens for humans.
Each one has a number
of antigens which
are usually protein
molecules, but not always,
that generate an immune response.
A very small number of those
antigens, in the pathogens,
provide protective immunity.
And so part of the
scientific discovery
is to find which ones are protective
and how to administer them,
so that a person generates a
lifelong protective response.
And in reality, in spite of there
being hundreds of pathogens,
really only a handful, 20
nominally, have been converted
into widely used vaccines.
And there's both scientific
problems and manufacturing problems
that have limited this conversion
of scientific knowledge
into useful products.
So today, here, we're
going to talk about what's
involved in making
widely used vaccines,
starting with the
scientific discovery.